Genfit S.A. - Asset Resilience Ratio
Genfit S.A. (GNFT) has an Asset Resilience Ratio of 64.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Genfit S.A. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Genfit S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GNFT total assets.
Liquid Assets Composition Over Time
This chart breaks down Genfit S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GNFT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €101.09 Million | 64.01% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €101.09 Million | 64.01% |
Asset Resilience Insights
- Very High Liquidity: Genfit S.A. maintains exceptional liquid asset reserves at 64.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genfit S.A. Industry Peers by Asset Resilience Ratio
Compare Genfit S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Biohaven Ltd.
NYSE:BHVN |
Biotechnology | 16.03% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Genfit S.A. (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Genfit S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.40% | €64.21 Million ≈ $75.07 Million |
€151.42 Million ≈ $177.03 Million |
+3.56pp |
| 2023-12-31 | 38.84% | €67.53 Million ≈ $78.95 Million |
€173.87 Million ≈ $203.27 Million |
-18.52pp |
| 2022-12-31 | 57.36% | €123.64 Million ≈ $144.55 Million |
€215.54 Million ≈ $251.99 Million |
+33.13pp |
| 2021-12-31 | 24.23% | €68.26 Million ≈ $79.80 Million |
€281.72 Million ≈ $329.36 Million |
-59.37pp |
| 2020-12-31 | 83.60% | €166.03 Million ≈ $194.11 Million |
€198.61 Million ≈ $232.20 Million |
-1.33pp |
| 2019-12-31 | 84.93% | €263.15 Million ≈ $307.65 Million |
€309.85 Million ≈ $362.25 Million |
-5.69pp |
| 2016-12-31 | 90.61% | €150.61 Million ≈ $176.08 Million |
€166.21 Million ≈ $194.32 Million |
+90.58pp |
| 2015-12-31 | 0.03% | €22.00K ≈ $25.72K |
€69.26 Million ≈ $80.97 Million |
-4.61pp |
| 2014-12-31 | 4.64% | €4.01 Million ≈ $4.69 Million |
€86.37 Million ≈ $100.97 Million |
+4.64pp |
| 2013-12-31 | 0.00% | €400.00 ≈ $467.64 |
€29.15 Million ≈ $34.08 Million |
-0.07pp |
| 2012-12-31 | 0.08% | €18.00K ≈ $21.04K |
€23.58 Million ≈ $27.57 Million |
+0.03pp |
| 2011-12-31 | 0.05% | €13.80K ≈ $16.13K |
€29.08 Million ≈ $33.99 Million |
-1.96pp |
| 2008-12-31 | 2.00% | €921.40K ≈ $1.08 Million |
€45.99 Million ≈ $53.77 Million |
-1.85pp |
| 2007-12-31 | 3.85% | €1.55 Million ≈ $1.81 Million |
€40.21 Million ≈ $47.01 Million |
+0.60pp |
| 2006-12-31 | 3.25% | €1.50 Million ≈ $1.76 Million |
€46.24 Million ≈ $54.06 Million |
-2.21pp |
| 2005-12-31 | 5.46% | €1.68 Million ≈ $1.97 Million |
€30.83 Million ≈ $36.05 Million |
-33.51pp |
| 2004-12-31 | 38.96% | €11.93 Million ≈ $13.94 Million |
€30.61 Million ≈ $35.78 Million |
-- |
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase… Read more